Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression

Citation
Mj. Hohol et al., Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression, MULT SCLER, 5(5), 1999, pp. 349-354
Citations number
24
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
MULTIPLE SCLEROSIS
ISSN journal
13524585 → ACNP
Volume
5
Issue
5
Year of publication
1999
Pages
349 - 354
Database
ISI
SICI code
1352-4585(199910)5:5<349:DSIMSA>2.0.ZU;2-B
Abstract
Clinical assessment of outcome in Multiple Sclerosis (MS) patients is probl ematic since the disease can affect different aspects of the central nervou s system and follow a variable course. Recently, we developed Disease Steps , a simple approach for evaluating disease progression. Previously, we foun d that Disease Steps was easy to use, had uniformly distributed scores and low inter-rater variability. Our current objective was to test the long-ter m use of Disease Steps together with the most widely utilized clinical outc ome measure in MS, the Expanded Disability Status Scale (EDSS) in assessing clinical progression. Over 4 years, 804 patients were classified using bot h EDSS and Disease Steps. Each patient was assessed at least twice. Follow- up results included annual status and time-to-event analysis examining medi an staying limes within a level of Disease Steps or EDSS. We found that the two scales behaved similarly and correlated strongly with each other. For both Disease Steps and EDSS, patients with milder levels of disability and relapsing-remitting disease demonstrated a higher likelihood of changing sc ores over lime and shorter median staying times compared to more disabled, chronic Progressive patients. These findings have important implications fo r patient selection in clinical trials and for the design of future measure ments of clinical outcome in MS. Furthermore, Disease Steps may serve as a simple, practical tool for the nonspeciality neurologist to follow patients over time and serve as a guide in therapeutic decision making. Our finding s further document the general progressive nature of MS when a large cohort is followed in an MS specialty clinic over time.